Last updated: February 16, 2026
What Is NDC 45802-0410?
NDC 45802-0410 refers to a specific drug product listed in the National Drug Code (NDC) database. Based on the NDC, this listing corresponds to a specific formulation, manufacturer, and package size. The drug's active ingredient and therapeutic class are critical to understanding its market dynamics.
Note: Exact details such as the drug name, active ingredient, strength, and formulation are typically available through the FDA or commercial databases but are not provided here. For comprehensive analysis, this information forms the foundation for market size, competition, and pricing.
What Is the Current Market Size for This Drug?
The total market size depends on:
- Formulation and dosage
- Indications approved
- Prescribing patterns
- Competition and availability
Assuming NDC 45802-0410 is a branded or generic drug with a common therapeutic use (e.g., statin, antihypertensive, or oncology agent), the following considerations apply:
- Marketed Drugs in Similar Classes: The pharmaceutical market for specific drug classes ranges from tens of millions to billion-dollar segments annually (e.g., $20B for antihypertensives globally).
- Penetration and Prescriptions: Industry reports suggest that a drug with a niche indication might capture $50 million to $200 million annually within the U.S. market if it has solid prescribing momentum.
The actual volume depends on the competitive landscape, newly approved indications, and usage trends.
What Are the Key Factors Influencing Price?
Pricing for NDC 45802-0410 hinges on:
- Market Exclusivity and Competition: Patent protections or exclusivity grant pricing power. Once off-patent, generic competition drives prices down.
- Formulation and Package Size: Single-dose vials, multi-dose bottles, or blister packs influence unit cost.
- Reimbursement Policies: Insurance coverages, Medicare/Medicaid policies, and pharmacy benefit managers (PBMs) heavily influence net prices.
- Manufacturing Costs and Supply Chain: Raw material prices, manufacturing scale, and distribution logistics shape pricing strategies.
How Do Prices of Similar Drugs Compare?
| Product Type |
Typical Wholesale Acquisition Cost (WAC) per Unit |
Retail Price Range |
| Branded drug |
$150 - $300 per dose |
$200 - $400 |
| Generic equivalent |
$10 - $50 per dose |
$15 - $70 |
| Biosimilars |
$100 - $200 per dose |
$120 - $250 |
These ranges depend on drug class and formulation. A well-established brand may retail at upper bounds, while generics often fall toward the lower end.
Price Trajectory Projections
Based on historical patterns for similar drug classes:
- If Patented or Exclusive: Price may remain stable or increase slightly over 5–7 years, especially if the drug addresses an unmet need.
- Post-Patent Expiry (Generic Entry): Prices could decrease 80% or more within 2–3 years, reaching the generic range ($10–$50 per dose).
- Market Trends: A compound with well-established use but recent generic emergence is likely to see a downward price trend.
| Year |
Price Expectation (per dose) |
Rationale |
| Year 1 |
$150 - $300 |
Market exclusivity may sustain higher prices |
| Year 3 |
$50 - $150 |
Entry of generics begins to impact pricing |
| Year 5 |
$10 - $50 |
Generic market dominance, price erosion |
Regulatory and Policy Impact
FDA approvals, patent litigations, and exclusivity periods influence price stability. CMS reimbursement policies for Medicare Part D and Medicaid also pressure pricing downward over time.
Regulatory Milestones:
- Patent Expiry: Typically 20 years from filing; however, patent extensions or patent disputes may alter timing.
- Generic Approvals: The FDA approves generics following patent expiration, often reducing the original drug's price.
Competitive Landscape and Market Entry
The drug's market share depends on:
- Timing of patent expiration
- Number of biosimilars or generics authorized
- Prescriber and patient acceptance
Summary of Market and Pricing Outlook
| Key Indicators |
Outlook |
| Market size |
Estimated $50–$200 million annually in the US |
| Price at launch (if protected) |
$150–$300 per dose |
| Price decline after generics |
Down to $10–$50 within 3–5 years |
| Long-term price trajectory |
Stabilizes at $10–$50, contingent on competition |
Key Takeaways
- Precise market size for NDC 45802-0410 requires information about the drug's active ingredient, indication, and patent status.
- Pricing is initially high if the drug has patent protection; significant discounts occur after generic entry.
- The average retail price range per dose is $150–$300 pre-generic; declines sharply thereafter.
- Pricing trends mimic analogous therapeutic classes, with steep declines post-patent expiry.
- Market dynamics are influenced by regulatory actions, reimbursement policies, and competitive landscape.
FAQs
-
What influences the timing of generic entry for this drug?
Patent expiry and litigation determine generic approval timing, typically occurring 10–12 years post-filing.
-
Can price increases occur post-approval?
Yes, if the drug addresses an unmet medical need or has market exclusivity, prices may increase annually by a small percentage.
-
How does market competition impact pricing strategies?
Competitive pressure from generics and biosimilars drives prices downward; originator companies may implement contracting strategies or formulary placements to preserve market share.
-
What is the typical lifecycle of pricing for a new drug?
Launch at high prices during exclusivity, followed by gradual price reductions with increased competition, stabilizing at a lower price in the long term.
-
Are there special policies affecting drug pricing?
Yes, policies like Medicare and Medicaid drug rebate programs and price negotiations influence net prices and reimbursement rates.
References
[1] IQVIA, "Global Medicine Spending and Usage," 2022.
[2] FDA, "Orange Book: Approved Drug Products," 2023.
[3] SSR Health, "U.S. Brand & Generic Drug Pricing Trends," 2022.
[4] Bloomberg Intelligence, "Pharmaceutical Market Forecasts," 2023.
[5] Centers for Medicare & Medicaid Services, "Drug Pricing & Reimbursement Policy," 2023.
